Metabolic Syndrome

Abstract

Objectives: The objective of this study was to investigate the importance ofindividual IHD risk factors and major components of the metabolic syndrome associated withIHD. Study Design: Descriptive cross sectional study. Setting: Cardiology Department ofGulab Devi Chest Hospital Lahore. Period: Nov, 2015 to Feb, 2016. Methodology: Patientsof either gender and from 20 to 90 year of age admitted with IHD via emergency departmentwere recruited after informed consent. The frequency of metabolic syndrome was evaluated inthese patients. In addition the individual component of metabolic syndrome as risk factor of IHDwas calculated. The data was analysed by using the SPSS version.16. Results: The metabolicsyndrome present in 44.67%of IHD patients and more prevalent in men 52% than in women48%. Total of 150 patients of IHD studied with both gender as male 94(63.33%) vs female 55(36.67%). The most common risk factor of metabolic syndrome for IHD was high blood pressurepresent in 75% of patients followed by diabetes in 50%, abdominal obesity 40.67%, low HDL42.67% and high TG in 32%. Conclusion: The metabolic syndrome is highly prevalent amongIHD patients especially in men. The most common risk factors are hypertension and diabetes.

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

“…Since its approval, rituximab's therapeutic indications were extended and presently include numerous other B-cell malignancies, autoimmune diseases, inflammatory disease, paraneoplastic pemphigus, pemphigus vulgaris, hypocomplementemic urticarial vasculitis, autoimmune cytopenias, and humoral organ transplant rejection. Rituximab is also prescribed for multicentric Castleman's disease and primary effusion lymphoma [11,25].…”

“…There is evidence, albeit limited, of the efficacy of treatment with valganciclovir. It was demonstrated that treatment with valganciclovir can reduce HHV-8 viral load and that valganciclovir can be used in high-risk patients to prevent KS flare [25]. Prophylactic treatment with valganciclovir can be administered to patients at high risk of developing KS.…”

Rituximab‐induced serum sickness in immunobullous disorders: A case series

“…1 It is an FDA-approved drug for the management of autoimmune and lymphoproliferative disorders like Rheumatoid Arthritis (2), Pemphigus Vulgaris (PV), CD20 positive B-cell Non-Hodgkin's Lymphoma, and Chronic Lymphocytic Leukemia (CLL). [2][3][4] The off-label use of this treatment has also demonstrated efficacy in managing moderate to severe cases of mucous membrane pemphigoid (MMP). 5 Immediate infusion-related reactions including fever, cough, and dyspnea have been mentioned as a result of immunologic response.…”